biotech / news / / Devdiscourse
AstraZeneca Pharma India reported a 23 per cent decline in net profit to Rs 44.88 crore.
AstraZeneca Pharma India's Q4 FY26 net profit declined 23% to Rs 44.88 crore.
KEY POINTS
- Q4 FY26 revenue for AstraZeneca Pharma India rose 20.42% to Rs 578.61 crore.
- Total expenses in Q4 FY26 increased 27.36% to Rs 525.34 crore.
- Full-year FY26 net profit for AstraZeneca Pharma India surged 62% to Rs 187.52 crore.
- Full-year FY26 revenue growth was driven by Oncology, Biopharmaceuticals, and Rare Disease progress.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →